Edwards Lifesciences has announced new data on the Evoque transcatheter tricuspid valve replacement (TTVR) system, shared at the American College of Cardiology’s annual scientific session (ACC.26; 28–30 March, New Orleans, USA) demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the 2025 European Society of Cardiology Congress (ESC).
The new TRISCEND II trial data demonstrated confidence in two-year performance of TTVR with the Evoque system and showed significant and sustained near elimination of tricuspid regurgitation (TR); improvements in health status and quality of life; no added device-related risk; and, significantly lower all-cause mortality when accounting for patient crossover.
“There is a significant patient population suffering with debilitating symptoms from tricuspid regurgitation with very limited treatment options. It’s not a surprise that the sickest patients enrolled in the medical therapy control group of the randomised TRISCEND II trial opted to receive treatment with the Evoque system following the one-year primary endpoint, underscoring both the benefits of and need for TTVR therapy,” said Vinod Thourani (Piedmont Heart Institute, Atlanta, USA). “Our analyses, including the many highly symptomatic crossover patients, showed significantly improved outcomes for all of the Evoque treated patients.”
The 18-month data of the TRISCEND II trial were presented at ESC in August 2025, showing achievement of a hard endpoint benefit for the most severe TR patients who received the EVOQUE therapy, and superior quality of life benefits, regardless of baseline TR.
“Edwards remains focused on developing innovative solutions that meet the most pressing needs of patients with structural heart disease, and we’re proud of the life-changing benefits demonstrated with the Evoque system,” said Daveen Chopra, Edwards’ corporate vice president, transcatheter mitral and tricuspid therapies. “In addition to TRISCEND I and II data, the growing body of evidence on Evoque includes data on more than 1,000 patients in the STS/ACC TVT Registry presented at TCT last year, demonstrating consistent near elimination of tricuspid regurgitation, improved quality of life, and a positive real-world safety profile across the broad tricuspid patient population.”
The Evoque system is approved in both the US and Europe.
